Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
09/2003
09/18/2003US20030175326 Palatable controlled-release formulations for companion animals
09/18/2003US20030175317 Multiple emulsions
09/18/2003US20030175315 Nanoemulsion comprising metabolites of ginseng saponin as an active component and a method for preparing the same, and a skin-care composition for anti-aging containing the same
09/18/2003US20030175314 Pharmaceutical composition for dermal application
09/18/2003US20030175313 Preparation of sterile stabilized nanodispersions
09/18/2003US20030175309 Adjuvants for use in vaccines
09/18/2003US20030175308 Adjuvants for use in vaccines
09/18/2003US20030175299 Comprising lecithin, oils, amphiphilic surfactant and an antigen; for protecting pig against a Bordetella infections and/or a toxigenic Pasteuralla infections; stable oil-in-water emulsions, side effect reduction
09/18/2003US20030175298 Comprising lecithin, oils, amphiphilic surfactant and an antigen; for protecting pig against a Bordetella infections and/or a toxigenic Pasteuralla infections
09/18/2003US20030175290 Molecular antigen array
09/18/2003US20030175289 TIE ligands
09/18/2003US20030175282 Photodynamic therapy comprising administering angiogenesis factor antagonists and photosensitizers then irradiating with lasers, for prophylaxis of vision defects
09/18/2003US20030175276 Monoclonal antibodies used as antagonists vascular endothelial growth factors (VEGF); angiogenesis inhibitors; antitumor agents
09/18/2003US20030175264 Comprises proteolytic enzymes; free of plasminogen activator
09/18/2003US20030175239 Protein crystals are encapsulated within a matrix of a biocompatible polymeric carrier; enhance preservation of the native biologically active tertiary structure of the protein, creates reservoir for slow release of protein when needed
09/18/2003US20030175238 Chemokine conjugates
09/18/2003US20030175214 Free-flowing fine particle mixtures comprising carrier particles, active drug particles and stabilizer particles, for respiratory system disorders; medical equipment
09/18/2003US20030175209 Image diagnosis of a brain tumor, renal carcinoma; tumor treatment therapies, immunotherapy
09/18/2003US20030175208 Treating a cancer of the immune system
09/18/2003US20030175206 Administering large liposomes to retend radioactive decay intermediates
09/18/2003US20030175205 Comprising a radioactive materials for detecting and/or quantifying diseases or conditions associated with cancer, infections, inflammation; a 2-propane carboxylic ester with a attached phosphatidic acid group
09/18/2003US20030173513 Probe for mass spectrometry
09/18/2003US20030173219 Devices and formulations
09/18/2003US20030172924 Medicament storage and delivery devices
09/18/2003DE20121877U1 Module for suppressing leukocyte activity, useful e.g. in association with heart-lung machines, comprises a carrier linked to a ligand specific for the leukocyte receptor
09/18/2003CA2813780A1 Genetic products differentially expressed in tumors and use thereof
09/18/2003CA2671976A1 Methods of inducing terminal differentiation
09/18/2003CA2478846A1 Use of mixtures of lipopeptides for vaccine production
09/18/2003CA2478685A1 Ophthalmic solutions containing tetrazole derivatives
09/18/2003CA2478684A1 Dispersed solid-containing complex carbohydrate
09/18/2003CA2478683A1 Antibodies against cancer antigen tmeff2 and uses thereof
09/18/2003CA2478522A1 Novel curcuminoid-factor viia constructs as suppressors of tumor growth and angiogenesis
09/18/2003CA2478510A1 Genomic screen for epigenetically silenced tumor suppressor genes
09/18/2003CA2478317A1 Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
09/18/2003CA2478239A1 The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
09/18/2003CA2478116A1 Neoplasm specific antibodies and uses thereof
09/18/2003CA2478082A1 Uses of monoclonal antibody 8h9
09/18/2003CA2477982A1 Methods for entrapment of bioactive agent in a liposome or lipid complex
09/18/2003CA2477979A1 An inhalation system for treatment of intracellular infections
09/18/2003CA2477701A1 Controlled release dosage forms
09/18/2003CA2477393A1 Ibuprofen solution for hard shell capsules
09/18/2003CA2477329A1 Controlled delivery patch of active ingredient
09/18/2003CA2475738A1 Activated protein c formulations
09/18/2003CA2474613A1 Sustained release drug formulations containing a carrier peptide
09/17/2003EP1344826A1 Materials comprising and methods of preparation and use for ribosome - inactivating proteins
09/17/2003EP1344533A1 Pharmaceutical compositions comprising mannose binding lectin
09/17/2003EP1344523A1 Ibuprofen solution for hard gelatin capsules
09/17/2003EP1344522A1 Transdermal therapeutic system for Parkinson's disease inducing high plasma levels of rotigotine
09/17/2003EP1344518A2 Cosmetic and pharmaceutical compositions containing oxyalkylated polyglycerol esters
09/17/2003EP1344517A1 Stable dispersion concentrates
09/17/2003EP1344516A1 Antioxidative composition
09/17/2003EP1344460A1 Egg having active oxygen eliminating ability and method of producing same
09/17/2003EP1343810A2 Diaminodicarboxylic acid: peptide-based gemini surfactant compounds used for drug delivery
09/17/2003EP1343805A1 Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
09/17/2003EP1343581A2 Instant water dissolvable encapsulate and process
09/17/2003EP1343542A2 Carrier with solid fibrinogen and solid thrombin
09/17/2003EP1343531A2 Conjugates of antibodies and anticancer drugs
09/17/2003EP1343530A1 Oral pharmaceutical composition containing a block copolymer
09/17/2003EP1343529A2 Nsaid formulations comprising lecithin oils for protecting the gastrointestinal tract and providing enhanced therapeutic activity
09/17/2003EP1343526A2 Vaccine
09/17/2003EP1343525A2 IMPROVED i MYCOPLASMA HYOPNEUMONIAE /i BACTERIN VACCINE
09/17/2003EP1343521A2 Method for the stabilizing biomolecules (e.g. insulin) in liquid formulations
09/17/2003EP1343518A2 Stabilized inteferon compositions
09/17/2003EP1343515A1 Compounds for sustained release of orally delivered drugs
09/17/2003EP1343511A1 Shark meat extract
09/17/2003EP1343508A1 Use of an oestrogen in the manufacture of a composition containing oestrogen for the treatment of atrophic vaginitis
09/17/2003EP1343504A2 Pharmaceutical formulation of gepirone for oral administration
09/17/2003EP1343492A2 Treatment of mucositis
09/17/2003EP1343488A1 Treatment of statin side effects
09/17/2003EP1343486A1 Pharmaceutical or cosmetic composition and use of a pkc inhibitor with an mmp inhibitor for inhibiting langerhans' cell migration
09/17/2003EP1343484A2 Transdermal systems (tds) that contain inhibitors of phosphodiesterase iv
09/17/2003EP1343483A2 Transdermal system containing a novel high potency progestagen
09/17/2003EP1343480A2 Induced phase transition method for the production of microparticles containing hydrophobic active agents
09/17/2003EP1343478A2 Induced phase transition method for the production of microparticles containing hydrophilic active agents
09/17/2003EP1343476A2 Preparation of large liposomes by infusion into peg
09/17/2003EP1343475A2 Self forming, thermodynamically stable liposomes and their applications
09/17/2003EP1343474A2 Intraocular irrigating solution having improved flow characteristics
09/17/2003EP1343473A1 Pharmaceutical dronedarone composition for parenteral administration
09/17/2003EP1343444A2 Solution for removing cataracts via liquefracture
09/17/2003EP1343372A2 Pulmonary delivery of polyene antifungal agents
09/17/2003EP1207875B1 Pharmaceutically stable oxaliplatinum preparation for parenteral administration
09/17/2003EP1150655B1 Use of nanoscale chitosanes
09/17/2003EP1140135B1 Cyclosporin solution
09/17/2003EP1140013B1 Foaming antacid suspension tablets
09/17/2003EP1100471B1 Compressed compositions comprising clarified xanthan gum
09/17/2003EP1033973B1 Encapsulation method
09/17/2003EP0938300B1 Substituted amylose as a matrix for sustained drug release
09/17/2003EP0909184B1 Targeted drug delivery using sulfonamide derivatives
09/17/2003EP0874623B1 Water activatable adhesive matrix containing amethocaine
09/17/2003EP0792165B1 Immunogenic compositions
09/17/2003EP0766960B1 External preparations for treating dermatoses
09/17/2003EP0669988B1 Angiogenesis inhibitory antibodies
09/17/2003CN1443196A Protein complex serving as vehicle for orally administerable medicaments
09/17/2003CN1443155A Compounds to treat alzheimer's disease
09/17/2003CN1443079A Polymeric conjugates of antitumor agents
09/17/2003CN1443078A Testosterone ester formulation for human use
09/17/2003CN1443076A Porcine reproductive and respiratory syndrome virus (PRRSV) recombinant avipoxvirus vaccine
09/17/2003CN1443072A Compositions containing ascorbic acid phosphoric acid esters
09/17/2003CN1443069A Sustained release ranolazine formulations
09/17/2003CN1443065A Pharmaceutical composition improved in peroral absorbability
1 ... 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 ... 1712